Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plazomicin - Cipla

Drug Profile

Plazomicin - Cipla

Alternative Names: [14C]-plazomicin; ACHN-490; Plazomicin sulfate; ZEMDRI

Latest Information Update: 11 Jan 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Cipla USA
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pyelonephritis; Urinary tract infections
  • Preregistration Bacteraemia; Nosocomial pneumonia
  • No development reported Gram-negative infections; Respiratory tract infections; Tularaemia; Yersinia infections

Most Recent Events

  • 07 Jan 2021 Cipla initiates a phase I pharmacokinetic trial in Healthy volunteers with renal failure in USA (IV, Infusion) (NCT04699656)
  • 16 Jun 2020 Cipla withdraws marketing authorisation application for Urinary tract infections (Complicated) in European Union
  • 21 Feb 2020 Xuanzhu (HK) Biopharmaceutical Limited acquires rights for plazomicin in China, Taiwan, Hong Kong and Macau
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top